3605-01-4
3605-01-4
Chemical Structure
Piribedil
- CAS No.: 3605-01-4
- Formula:C16H18N4O2
- Molecular Weight:298.34
IUPAC Name: 2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)pyrimidine
InChIKey: OQDPVLVUJFGPGQ-UHFFFAOYSA-N
SMILES: C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1
Biological Activity: Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Piribedil | 99.92% | Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil (Standard) | ≥98% | Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil-d8 | 99.79% | Piribedil-d8 is the deuterium labeled Piribedil, which is an antiparkinsonian agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil-d4 | Piribedil-d4 is the deuterium labeled Piribedil (HY-12707). Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil dihydrochloride | Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil maleate | Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a α2-adrenoceptors antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil hydrochloride | Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a α2-adrenoceptors antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil N-oxide | Piribedil N-oxide is a metabolite of the dopamine receptor agonist Piribedil (HY-12707). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fipexide hydrochloride (Standard) | ≥98% | Fipexide (hydrochloride) (Standard) is the analytical standard of Fipexide (hydrochloride). This product is intended for research and analytical applications. Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fipexide (Standard) | ≥98% | Fipexide (Standard) is the analytical standard of Fipexide. This product is intended for research and analytical applications. Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
1-Piperonylpiperazine | 98.02% | 1-Piperonylpiperazine (MDBP) is metabolized by demethylenation and subsequent methylation to N-(4-hydroxy-3-methoxybenzyl)piperazine followedby partial glucuronidation or sulfation. 1-Piperonylpiperazine can alter the disposition and metabolism of 3,4-methylenedioxymethamphetamine (MDMA) in the brain and in peripheral organs. 1-Piperonylpiperazine can inhibit the MDMA-induced neurotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MDBP hydrochloride | MDBP hydrochloride is a piperazine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
S584 dihydrochloride | S584 dihydrochloride is a catechol metabolite of the oral-effective Piribedil (HY-12707), with anti-lipid peroxidation activity. S584 dihydrochloride significantly inhibits lipid peroxidation in rat synaptosomes under basal conditions and Fe³⁺ stimulation. S584 dihydrochloride significantly antagonizes the increase in thiobarbituric acid reactive substances (TBARS) in the brains of mice exposed to high oxygen and under normal air conditions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16(6):1077-82. [Content Brief]
- [2]. Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. J Neural Transm (Vienna). 2013 Jan;120(1):31-6. [Content Brief]
- [3]. Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17(5):887-901. [Content Brief]
- [4]. Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160. [Content Brief]
